《大行報告》瑞信下調華潤醫療(01515.HK)目標價至6.8元 評級「中性」
瑞信發表報告指,華潤醫療(01515.HK)去年下半年收入按年增長60.2%,主要是收購的濟南重汽醫院,及整合淮礦醫院集團和潤能系醫院的貢獻。至於下半年純利受到疫情影響,按年下跌0.9%。
報告稱,由於醫院整合及新冠疫情影響,去年下半年毛利率按年收窄15個百分點。下半年淨利潤率收窄7.1個百分點。展望未來,該行料華潤醫療淨利潤率將接近2020年水平。
該行下調華潤醫療股份目標價,由7元降至6.8元,評級維持「中性」,並調低集團今明兩年盈利預測各16%,以反映疫情影響更長,令復甦步伐放緩。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.